1 January–31 December
|
kEUR |
2024 |
2023 |
|
|
|
|
|
|
|
Revenue |
336,792 |
320,372 |
|
|
Other operating income |
1,978 |
4,481 |
|
|
Total income |
|
338,770 |
324,853 |
|
|
|
|
|
|
Cost of sales |
|
-299,422 |
-315,730 |
|
Gross profit / (loss) |
|
39,348 |
9,123 |
|
|
|
|
|
|
Marketing and sales expenses |
-3,866 |
-4,053 |
|
|
Research expenses |
-1,095 |
-1,465 |
|
|
General and administrative expenses |
-41,751 |
-40,073 |
|
|
Total operating expenses |
|
-46,712 |
-45,591 |
|
|
|
|
|
|
Operating result (EBIT) |
|
-7,364 |
-36,468 |
|
|
|
|
|
|
Financial income |
6,802 |
103 |
|
|
Financial expenses |
-17,583 |
-21,878 |
|
|
Total financial result |
|
-10,781 |
-21,775 |
|
|
|
|
|
|
Result before income taxes |
|
-18,145 |
-58,243 |
|
|
|
|
|
|
Income tax |
-1,419 |
6,803 |
|
|
Result for the year |
|
-19,564 |
-51,440 |
|
|
|
|
|
|
Attributable to shareholders of PolyPeptide Group AG |
|
-19,564 |
-51,440 |
|
|
|
|
|
|
Earnings per share in EUR, basic |
-0.59 |
-1.56 |
|
|
Earnings per share in EUR, diluted |
-0.59 |
-1.56 |